TRVN240517C2500
- 0.05
- 0.000.00%
Trevena Newsroom
Express News | HC Wainwright & Co. Maintains Buy on Trevena, Lowers Price Target to $5
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising Drug TRV045
Analysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)
Trevena | 10-Q: Quarterly report
Express News | Trevena- Got Letter From Nasdaq Hearings Panel Granting Extension Until August 28, to Regain Compliance With Nasdaq Continued Listing Requirements
Express News | Trevena Q1 2024 GAAP EPS $(0.36) Beats $(0.47) Estimate, Sales $20.000K Up From $6.000K YoY
Earnings Flash (TRVN) TREVENA Reports Q1 Revenue $20,000
07:04 AM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (TRVN) TREVENA Reports Q1 Revenue $20,000
Express News | Trevena Inc - Continues Its Review of Strategic Alternatives for Olinvyk
Express News | Trevena Reports First Quarter 2024 Results and Provides Business Update
Express News | Trevena Q1 Net Income USD -7.7 Million
Express News | Trevena Q1 EPS USD -0.36
Trevena 1Q Loss $7.68M >TRVN
Trevena 1Q Loss $7.68M >TRVN
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTrevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. Mustang Bio (NASDAQ:MBIO) stock increased by 1
Trevena Is Maintained at Buy by HC Wainwright & Co.
Trevena Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
Recap: Trevena Q4 Earnings
Trevena (NASDAQ:TRVN) reported its Q4 earnings results on Monday, April 1, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsTrevena missed estimated earnings by -179.